Variant is a biotechnology company that develops innovative products in the ophthalmology sector. Variant aims to provide the pharmaceutical industry with solid proof-of-concept data to enable the clinical development of therapeutic strategies intended for rare visual diseases. The company has several scientific collaborations specialized in genome analysis, production and administration of AAV vectors, and human retinal organoids. Our associated partners are well-positioned to test therapies for dominant and recessive retinal dystrophy forms, notably orphan diseases, such as congenital Leber Amaurosis, cone-rod dystrophies, and retinitis pigmentosa. Variant’s leading preclinical portfolio has a diversified risk profile: the company specializes in the use of “transcription factor” genes, which intervene very early in the development of photoreceptors to relaunch the differentiation of cones and rods in the retina.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 9 Rue De L'éperon, Paris,île-De-France 75006,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.variant.paris/
- Keywords
- Paris.
- HQ
- Paris, Île-de-France
Variant Questions
Variant's website is https://www.variant.paris/
Variant's LinkedIn profile is https://fr.linkedin.com/company/variant-paris
Variant has
2 employees.
View email and phone details for 2
employees at Variant.
Variant's industry is
Biotechnology Research
Variant's top competitors are
Variant Pharmaceuticals Private Limited,
Rose,
Fondation Stargardt,
Institut De La Vision,
Fondazione Banca Degl Occhi Del Veneto Ets,
Fahmir Pharma (Pvt.) Ltd.,
Labwear Studios,
Conveyxo,
Variant Pharma,
Mister Ia.
Variant's categories are Biotechnology Research
Variant's founding year is 2017
